Effect of Spironolactone Versus Placebo on Atrial Fibrillation/Flutter and Bradycardia or Conduction Blocks
bradycardia, atrial fibrillation/flutter
EVENTS, ATRIAL FIBRILLATION/FLUTTER
The higher frequency of atrial fibrillation/flutter and bradycardia or conduction block events, compared with other events, permitted the estimation of RRs, according to the randomized groups. There were no significant associations of spironolactone (individual dose groups or combined) with atrial fibrillation/flutter, compared with placebo (Table Estimated rate ratios (95% confidence intervals) for atrial fibrillation/flutter and bradycardia/conduction blocks, according to randomized treatment groupModels (independence correlation) included the exposure of interest and study visits.Models (independence correlation) included the exposure of interest, study visits, length of time on dialysis, and current angiotensin converting enzyme inhibitor/angiotensin receptor blocker use.A dose-related, but nonsignificant, increase in bradycardia or conduction block events with spironolactone was observed, with a RR of 3.0 (95% confidence interval [CI] 0.80–11.20) for the 50 mg group and 1.45 (95% CI 0.61–3.44) for the 25 mg group, compared with placebo. Similarly, there was an approximately two-fold higher risk of bradycardia or conduction block events for the combined spironolactone group versus placebo (RR 2.04; 95% CI 0.83–5.05 [Table 